Pomalong

Pomalong Uses, Dosage, Side Effects, Food Interaction and all others data.

Pomalong, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Pomalong is more potent than thalidomide (100-times) and lenalidomide (10-times).

Trade Name Pomalong
Availability Prescription only
Generic Pomalidomide
Pomalidomide Other Names Pomalidomida, Pomalidomide
Related Drugs paclitaxel, Revlimid, Taxol, Velcade, Darzalex, vinblastine, Pomalyst, interferon alfa-2b, Ninlaro, Doxil
Weight 1mg, 4mg
Type Capsule, Tablet
Formula C13H11N3O4
Weight Average: 273.2441
Monoisotopic: 273.074955855
Protein binding

12-44% protein bound. It is not concentration dependent.

Groups Approved
Therapeutic Class
Manufacturer Cipla Limited
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Pomalong
Pomalong

Uses

Pomalong is a thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma.

Pomalong is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Pomalong is also used to associated treatment for these conditions: Refractory Multiple Myeloma

How Pomalong works

Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.

Toxicity

Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.

Food Interaction

  • Take at the same time every day.
  • Take with or without food. Administration of pomalidomide with food reduces the AUC and Cmax by 8% and 27%, respectively, and delays Tmax by two and a half hours.

[Moderate] MONITOR: Cigarette smoking may reduce pomalidomide exposure due to induction of CYP450 1A2, the isoenzyme that is responsible for the metabolic clearance of pomalidomide along with CYP450 3A4.

MANAGEMENT: Patients should be advised that smoking may reduce the efficacy of pomalidomide therapy.

Pomalong should be taken on an empty stomach, at least 2 hours before or 2 hours after a meal.

Volume of Distribution

Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L

Elimination Route

Pomalong is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.

Half Life

Healthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.

Clearance

Total body clearance = 7-10 L/hour

Elimination Route

When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.

Innovators Monograph

You find simplified version here Pomalong

*** Taking medicines without doctor's advice can cause long-term problems.
Share